INSMED INC Proceeds from Sale and Maturity of Marketable Securities
INSMED INC (INSM) reported Proceeds from Sale and Maturity of Marketable Securities of $714.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- INSMED INC proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $430.00M, a 15.35% decline year-over-year.
- INSMED INC proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $284.00M, a 60.61% decline year-over-year.
- INSMED INC proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $436.00M, a 39.11% decline year-over-year.
- INSMED INC proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $425.00M.
- INSMED INC proceeds from sale and maturity of marketable securities for fiscal 2025 was $2.09B, a 105.71% increase from fiscal 2024.
- INSMED INC proceeds from sale and maturity of marketable securities for fiscal 2024 was $1.02B, a 170.93% increase from fiscal 2023.
- INSMED INC proceeds from sale and maturity of marketable securities for fiscal 2023 was $375.00M, a 400.00% increase from fiscal 2022.
- INSMED INC proceeds from sale and maturity of marketable securities for fiscal 2022 was $75.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $430.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $714.00M 10-Q · filed 2026-08-06 | $1.15B derived: sum of 3 quarters · filed 2026-08-06 | $1.57B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $284.00M 10-Q · filed 2026-05-07 | $720.00M derived: sum of 2 quarters · filed 2026-05-07 | $1.15B derived: sum of 3 quarters · filed 2026-05-07 | $1.65B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $436.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $861.00M derived: sum of 2 quarters · filed 2026-02-19 | $1.37B derived: sum of 3 quarters · filed 2026-08-06 | $2.09B 10-K · filed 2026-02-19 |
| 2025-09-30 | $425.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $933.00M derived: sum of 2 quarters · filed 2026-08-06 | $1.65B 10-Q · filed 2025-10-30 | $2.37B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $508.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.23B 10-Q · filed 2026-08-06 | $1.95B derived: sum of 3 quarters · filed 2026-08-06 | $1.95B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $721.00M 10-Q · filed 2026-05-07 | $1.44B derived: sum of 2 quarters · filed 2026-05-07 | $1.44B derived: sum of 3 quarters · filed 2026-05-07 | $1.44B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $716.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $716.00M derived: sum of 2 quarters · filed 2026-02-19 | $716.00M derived: sum of 3 quarters · filed 2026-02-19 | $1.02B 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $300.00M 10-Q · filed 2025-10-30 | $600.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $300.00M 10-Q · filed 2025-08-07 | $600.00M derived: sum of 3 quarters · filed 2026-02-19 | $610.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $300.00M 10-Q · filed 2025-05-08 | $600.00M derived: sum of 2 quarters · filed 2026-02-19 | $610.00M derived: sum of 3 quarters · filed 2026-02-19 | $630.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $300.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $310.00M derived: sum of 2 quarters · filed 2026-02-19 | $330.00M derived: sum of 3 quarters · filed 2026-02-19 | $375.00M 10-K · filed 2026-02-19 |
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $30.00M derived: sum of 2 quarters · filed 2024-10-31 | $75.00M 10-Q · filed 2024-10-31 | $100.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $65.00M 10-Q · filed 2024-08-08 | $90.00M derived: sum of 3 quarters · filed 2025-02-20 | $140.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $45.00M 10-Q · filed 2024-05-09 | $70.00M derived: sum of 2 quarters · filed 2025-02-20 | $120.00M derived: sum of 3 quarters · filed 2025-02-20 | $120.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $75.00M derived: sum of 2 quarters · filed 2025-02-20 | $75.00M derived: sum of 3 quarters · filed 2025-02-20 | $75.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $50.00M derived: sum of 2 quarters · filed 2023-10-26 | $50.00M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |